Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies

被引:82
作者
Mimeault, M
Brand, RE
Sasson, AA
Batra, SK
机构
[1] Univ Nebraska, Med Ctr, Eppley Canc Inst, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
[2] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Evanston NW Healthcare, Evanston, IL USA
[3] Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE USA
关键词
combination therapy; diagnosis; gemcitabine; epidermal growth factor epidermal growth factor receptor system; pancreas carcinogenesis;
D O I
10.1097/01.mpa.0000175893.04660.1b
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This review describes the recent advances in the molecular events involved in pancreatic cancer initiation, progression, and metastasis. Additionally, the importance of deregulated cellular signaling elements as potential targets for developing novel therapeutic strategies against incurable forms of pancreatic cancer is reported. The emphasis is on the critical functions gained by numerous growth factors and their receptors, such as epidermal growth factor receptor, hedgehog signaling, and proangiogenic agents such as vascular endothelial factor and interleukin-8 for the sustained growth, survival, and metastasis of pancreatic cancer cells. The molecular mechanisms associated with antitumoral properties and the clinical benefits of gemcitabine alone or in combination with other cytotoxic agents for the treatment of pancreatic cancer are discussed.
引用
收藏
页码:301 / 316
页数:16
相关论文
共 192 条
[21]  
Brand R, 2001, CANCER J, V7, P287
[22]   Hereditary pancreatic adenocarcinoma - A clinical perspective [J].
Brand, RE ;
Lynch, HT .
MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (03) :665-+
[23]  
Bruell D, 2003, INT J ONCOL, V23, P1179
[24]  
Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005
[25]  
Bruns CJ, 2000, CANCER RES, V60, P2926
[26]  
Bruns CJ, 2000, CLIN CANCER RES, V6, P1936
[27]  
Bruns CJ, 2000, CANCER RES, V60, P2
[28]   Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin) [J].
Büchler, P ;
Reber, HA ;
Büchler, MC ;
Roth, MA ;
Büchler, MW ;
Friess, H ;
Isacoff, WH ;
Hines, OJ .
JOURNAL OF GASTROINTESTINAL SURGERY, 2001, 5 (02) :139-146
[29]   Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression [J].
Büchler, P ;
Reber, HA ;
Büchler, MW ;
Friess, H ;
Lavey, RS ;
Hines, OJ .
CANCER, 2004, 100 (01) :201-210
[30]   Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid [J].
Büchler, P ;
Gukovskaya, TS ;
Mouria, T ;
Büchler, MC ;
Büchler, MW ;
Friess, H ;
Pandol, TJ ;
Reber, HA ;
Hines, OJ .
PANCREAS, 2003, 26 (03) :264-273